667 related articles for article (PubMed ID: 33804731)
1. Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies.
Fanelli GN; Grassini D; Ortenzi V; Pasqualetti F; Montemurro N; Perrini P; Naccarato AG; Scatena C
Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33804731
[TBL] [Abstract][Full Text] [Related]
2. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma Microenvironment and Invasiveness: New Insights and Therapeutic Targets.
Erices JI; Bizama C; Niechi I; Uribe D; Rosales A; Fabres K; Navarro-Martínez G; Torres Á; San Martín R; Roa JC; Quezada-Monrás C
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108208
[TBL] [Abstract][Full Text] [Related]
4. Astrocytes, the rising stars of the glioblastoma microenvironment.
Brandao M; Simon T; Critchley G; Giamas G
Glia; 2019 May; 67(5):779-790. PubMed ID: 30240060
[TBL] [Abstract][Full Text] [Related]
5. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
6. Cell-based therapies for glioblastoma: Promising tools against tumor heterogeneity.
Nehama D; Woodell AS; Maingi SM; Hingtgen SD; Dotti G
Neuro Oncol; 2023 Sep; 25(9):1551-1562. PubMed ID: 37179459
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapies for malignant glioma.
Boussiotis VA; Charest A
Oncogene; 2018 Mar; 37(9):1121-1141. PubMed ID: 29242608
[TBL] [Abstract][Full Text] [Related]
8. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy.
White K; Connor K; Meylan M; Bougoüin A; Salvucci M; Bielle F; O'Farrell AC; Sweeney K; Weng L; Bergers G; Dicker P; Ashley DM; Lipp ES; Low JT; Zhao J; Wen P; Prins R; Verreault M; Idbaih A; Biswas A; Prehn JHM; Lambrechts D; Arijs I; Lodi F; Dilcan G; Lamfers M; Leenstra S; Fabro F; Ntafoulis I; Kros JM; Cryan J; Brett F; Quissac E; Beausang A; MacNally S; O'Halloran P; Clerkin J; Bacon O; Kremer A; Chi Yen RT; Varn FS; Verhaak RGW; Sautès-Fridman C; Fridman WH; Byrne AT
Ann Oncol; 2023 Mar; 34(3):300-314. PubMed ID: 36494005
[TBL] [Abstract][Full Text] [Related]
9. ScRNA-seq reveals novel immune-suppressive T cells and investigates CMV-TCR-T cells cytotoxicity against GBM.
Long X; Zhang Z; Li Y; Deng K; Gao W; Huang M; Wang X; Lin X; She X; Zhao Y; Zhang M; Huang C; Wang S; Du Y; Du P; Chen S; Liu Q; Wu M
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38688579
[TBL] [Abstract][Full Text] [Related]
10. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.
Ye Z; Ai X; Zhao L; Fei F; Wang P; Zhou S
Oncogene; 2021 Oct; 40(42):6059-6070. PubMed ID: 34556813
[TBL] [Abstract][Full Text] [Related]
12. Immune Microenvironment in Glioblastoma Subtypes.
Chen Z; Hambardzumyan D
Front Immunol; 2018; 9():1004. PubMed ID: 29867979
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Endocannabinoid System Present in the Glioblastoma Tumour Microenvironment as a Potential Anti-Cancer Strategy.
Dasram MH; Naidoo P; Walker RB; Khamanga SM
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338649
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.
Poon CC; Sarkar S; Yong VW; Kelly JJP
Brain; 2017 Jun; 140(6):1548-1560. PubMed ID: 28334886
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-polyglycerol-nanodiamond composites stimulate glioblastoma cell immunogenicity through activation of autophagy.
Li TF; Xu YH; Li K; Wang C; Liu X; Yue Y; Chen Z; Yuan SJ; Wen Y; Zhang Q; Han M; Komatsu N; Zhao L; Chen X
Acta Biomater; 2019 Mar; 86():381-394. PubMed ID: 30654213
[TBL] [Abstract][Full Text] [Related]
16. Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment.
Widodo SS; Hutchinson RA; Fang Y; Mangiola S; Neeson PJ; Darcy PK; Barrow AD; Hovens CM; Dinevska M; Stylli SS; Mantamadiotis T
Cancer Immunol Immunother; 2021 Jul; 70(7):1811-1820. PubMed ID: 33389014
[TBL] [Abstract][Full Text] [Related]
17. Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations.
Niedbała M; Malarz K; Sharma G; Kramer-Marek G; Kaspera W
Onco Targets Ther; 2022; 15():437-468. PubMed ID: 35509452
[TBL] [Abstract][Full Text] [Related]
18. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
[TBL] [Abstract][Full Text] [Related]
19. Macrophages and microglia: the cerberus of glioblastoma.
Buonfiglioli A; Hambardzumyan D
Acta Neuropathol Commun; 2021 Mar; 9(1):54. PubMed ID: 33766119
[TBL] [Abstract][Full Text] [Related]
20. Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
Surendran A; Jenner AL; Karimi E; Fiset B; Quail DF; Walsh LA; Craig M
J Pharmacol Exp Ther; 2023 Oct; 387(1):66-77. PubMed ID: 37442619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
